Factory Supply Raw Material API Powder High Quality 99% CAS 141505-33-1 Levosimendan

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Model NO.: TY-02AL
• CAS: 141505-33-1
• Appearance: White Powder
• Einecs: 616-396-9
• Assay: 99%
• Shelf: 2 Years
• Transport Package: 25kg/Drum 5g, 100g, 500g, 1kg, 10kg, 100kg, 200kg
• Specification: 25kg/drum
• Trademark: tongyon
• Origin: China
• Production Capacity: 5000kg/Month

Product Description

 

Product name	Levosimendan
CAS	141505-33-1
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Product Name:Levosimendan
CAS:141505-33-1
MF:C14H12N6O
MW:280.28
EINECS:663-528-6
Mol File:141505-33-1.mol 
Melting point:216-219°C (dec.)
alpha D25 -566° (tetrahydrofurane/methanoll)
Density 1.33±0.1 g/cm3(Predicted)
storage temp. -20°C Freezer
solubility DMSO: ≥20mg/mL
pka6.3(at 25ºC)
form powder


 


Levosimendan was introduced in Sweden as an i.v. infusion for the treatment of acute heart failure or refractory symptoms of chronic heart failure in cases where conventional treatment (e.g., diuretic or ACE inhibitor) is not sufficient. Levosimendan is the (R)- enantiomer of simendan that belongs to the same class as pimobendan (Boehringer Ingelheim). Levosimendan is an innovative myofilament calcium sensitizer that increases myocardial contractility by selectively binding to the N-terminus of troponin C and by stabilizing the Ca2+-bound conformation of this contractile protein. It also activates ventricular and arterial adenostne triphosphate-regulated potassium channels which causes vasodilatation in vascular smooth muscle and protects myocardium against infarction. Its low phosphodiesterase III inhibiting activity is probably not responsible for its positive inotropic, lusitropic and dilating effects. Unlike other cardiotonic drugs, levosimendan is able to produce positive inotropic effects without prolonging myocardial relaxation or increasing the incidence of malignant arrythmias. It was clinically shown to have a lower risk of mortality in patients with heart failure when compared to placebo and dobutamine. Since it has a larger potential, levosimendan is currently under further clinical evaluation as a chronic treatment for congestive heart failure.


GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.